6533b7d7fe1ef96bd12690c1
RESEARCH PRODUCT
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients.
Alfredo BerrutiDaniele SantiniSalvatore Del PreteMaria Antonietta SatolliGiuseppa FerraroGiuseppe ToniniIlaria RoatoVincenzo AdamoAntonio RussoGaetano LanzettaRaffaele AddeoSara GalluzzoFilippo MontemurroMaura RossiV. LeoniBruno VincenziMauro AntimiMaria Rosaria ValerioMichele CaragliaVittorio FuscoStefania RedanaMonica Marrasubject
OncologyAdultMaleCancer Researchmedicine.medical_specialtySettore MED/06 - Oncologia MedicaAntineoplastic AgentsBreast NeoplasmsDrug resistanceAntibodies Monoclonal HumanizedMetastasisBreast Neoplasms MaleAntineoplastic AgentCohort StudiesBreast cancerRetrospective StudieTrastuzumabInternal medicinemedicineHumansskin and connective tissue diseasesMetastatic breast cancer; Smoking; Trastuzumab; Adult; Aged; Aged 80 and over; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms Male; Cohort Studies; Drug Resistance Neoplasm; Female; Humans; Male; Middle Aged; Retrospective Studies; Smoking; Cancer Research; OncologyneoplasmsAgedRetrospective StudiesGynecologyAged 80 and overbusiness.industrySmokingCancerAntibodies MonoclonalRetrospective cohort studyGeneral MedicineMiddle AgedTrastuzumabmedicine.diseaseMetastatic breast cancerOncologyDrug Resistance Neoplasmtrastuzumab smoking metastatic breast cancerFemalemetastatic breast cancerBreast diseaseCohort StudiebusinessBreast NeoplasmHumanmedicine.drugdescription
Many ErbB2-positive cancers may show intrinsic resistance, and the frequent development of acquired resistance to ErbB-targeted agents represents a substantial clinical problem. The constitutive NF-κB activation in some HER-2/neu positive breast cancer may represent a potential cause of resistance to trastuzumab therapy. Preclinical data revealed that 4-(N-Methyl-N- nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific nitrosamine is able to enhance NF-κB DNA binding activity and theoretically to increase the resistance to trastuzumab. Two hundred and forty-eight women with pathologically confirmed, uni- or bidimensionally measurable, HER-2-positive metastatic breast cancer (MBC) treated with trastuzumab-based therapy as first line combination for metastatic disease were considered eligible. For all included patients data on smoking habit were detectable from medical records. We retrospectively analysed the smoking habits of 248 MBC patients and correlated these habits with activity and efficacy of trastuzumab-based therapy. No statistically significant difference in terms of response rate (RR), time to progression (TTP) and overall survival (OS) was identified between smokers (former plus active smokers) and never smokers. Moreover, no statistically significant difference in terms of RR, TTP and OS was identified either comparing active smokers and former smokers. Moreover, we did not observed any significant statistical difference in terms of TTP and OS between smokers ≥10 cigarettes/day and ≤10 cigarettes/day. This study clearly showed lack of any correlation between cigarette smoking habit and both activity and efficacy of trastuzumab-based first line therapy in metastatic HER2/neu positive breast cancer patients. Copyright © 2011 Spandidos Publications Ltd. All rights reserved.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2011-01-01 |